Skip to Content

Clinical Trials Detail

Exenatide

Impact of Exenatide on Cardiovascular Exercise Performance

Objective

Previous research has shown that type 2 diabetes is linked with an impairment in exercise capacity. Impaired exercise capacity is a factor which is potentially associated with an increased risk of cardiovascular disease in those with type 2 diabetes.  Recent studies suggest that agents such as exenatide may have a beneficial effect on blood vessel and heart function.  Because these two factors are associated with exercise dysfunction, exenatide may improve exercise capacity in those with type 2 diabetes. 

The aims of this study are to (1) assess whether exenatide will improve exercise capacity in persons with type 2 diabetes and (2) investigate the effect of exenatide on specific metabolic, blood vessel and cardiac measures of function related to changes in exercise capacity. 

IRB Protocol Number
10-0438

All Other Trials

  • Women's Health
  • Exercise
  • Diabetes
  • Drugs (Pharmacology)
  • Heart & Circulation
Contact
Leah Herlache, MS at 720-848-6688
or leah.herlache@ucdenver.edu
Eligibility and Other Participant Information

This study will look at the effects of exenatide (a diabetes medication) on exercise capacity in people with type 2 diabetes

 

Qualified participants will receive:

- 3 months of treatment with exenatide or a placebo

- Blood tests

- Exercise testing

- Financial compensation

 

Inclusion Criteria:

* Men and women between the ages of 45 and 70 years of age

* Diagnosed with uncomplicated type 2 diabetes

* Sedentary persons

* Females who are post-menopausal

* BMI must be less than 35

* Subjects must be taking metformin for diabetes control and may also be on sulfonylurea drugs and/or meglitinides

* Non-smokers or former smokers who have quit for at least 1 year

 

Exclusion Criteria:

* People with T2DM taking oral medications, other than metformin, sulfonylurea drugs and/or meglitinides, to control their diabetes.

* Persons treated with insulin will be excluded

* People who are currently smoking or have not quit for at least one year

* Peripheral neuropathy

* Pulmonary problems that would limit exercise performance

* Renal disease

* Persons with peripheral arterial disease

* Persons with a history of pancreatitis